SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001558370-19-008878
Filing Date
2019-10-11
Accepted
2019-10-10 21:39:46
Documents
5
Period of Report
2019-10-10
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 1.02: Termination of a Material Definitive Agreement
Item 2.01: Completion of Acquisition or Disposition of Assets
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K f8-k.htm 8-K 51709
2 EX-2.1 ex-2d1.htm EX-2.1 613853
3 EX-99.1 ex-99d1.htm EX-99.1 14220
4 EX-99.2 ex-99d2.htm EX-99.2 473065
5 GRAPHIC ex-99d1g001.jpg GRAPHIC 19277
  Complete submission text file 0001558370-19-008878.txt   1180831
Mailing Address 640 LEE ROAD SUITE 200 WAYNE PA 19087
Business Address 640 LEE ROAD SUITE 200 WAYNE PA 19087 484-324-7933
Aclaris Therapeutics, Inc. (Filer) CIK: 0001557746 (see all company filings)

IRS No.: 460571712 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37581 | Film No.: 191146961
SIC: 2834 Pharmaceutical Preparations
Office of Life Sciences